Clinical trials
Systemic Sclerosis clinical trials
Below are recruiting systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 178 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06865118Recruiting
Home management of heart issues in scleroderma
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
OsloAges 18 years+ - NCT07047690RecruitingPhase 2
Nemolizumab for adults with scleroderma
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Ann Arbor, MichiganAges 18 years+ - NCT07236970Recruiting
AI screening for pulmonary hypertension in scleroderma
This study uses artificial intelligence to find better ways to screen for pulmonary arterial hypertension (a type of high blood pressure in the lungs) in people with systemic sclerosis (scleroderma). The goal is to catch the condition earlier so treatment can start sooner.
Granada, AndalusiaAges 18–80 - NCT07292961Recruiting
Exercise program for people with scleroderma
This study tests if a special exercise program based on your body and mind can help people with scleroderma feel better. It is for both children (ages 7-18) and adults.
Ankara, AltındağAges 7 years+ - NCT07335562RecruitingPhase 3
Comparing a new cell therapy (zola-cel) to standard care for active systemic sclerosis
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
Scottsdale, ArizonaAges 16 years+ - NCT07360808Recruiting
Fat Cell Therapy for Hand Problems in Scleroderma
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
Guangzhou, GuangdongAges 18–70 - NCT07641634RecruitingPhase 1/Phase 2
Testing PRO-203 for active systemic sclerosis
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
Melbourne, VictoriaAges 18–65 - NCT06658483Enrolling by invitation
Hand Scleroderma Experience Survey for People With Systemic Sclerosis
This study is testing a new scale to measure what it's like to live with hand problems caused by systemic sclerosis (scleroderma). By answering questions about your daily hand function, you can help doctors better understand your experience and improve care.
Malatya, MalatyaAges 18 years+ - NCT04132206Recruiting
Studying gut bacteria patterns in systemic sclerosis over time
This study looks at changes in gut bacteria over time in people with systemic sclerosis (a connective tissue disease). It also compares them with healthy adults to understand what gut bacteria patterns may be linked to this condition.
MarseilleAges 18 years+ - NCT07182968Recruiting
Turkish questionnaire for scleroderma patients
This study is adapting a questionnaire to measure how scleroderma affects your daily life. Your responses will help make the tool more useful for Turkish-speaking patients.
Çankaya, AnkaraAges 18 years+ - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Redwood City, CaliforniaAges 18–70 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT06375005RecruitingPhase 2
Telitacicept for early diffuse scleroderma
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Yangzhou, JiangsuAges 18–70 - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Mesa, ArizonaAges 18–70 - NCT06658470Enrolling by invitation
Hand disability in scleroderma with digital ulcers
This study looks at hand function and disability in people with systemic sclerosis who have digital ulcers. It aims to understand how these ulcers affect daily hand use.
Denizli, MalatyaAges 18 years+ - NCT04917705Recruiting
Blood and tissue tests to find markers in muscle and skin disease
This study looks for blood and tissue “biomarkers” (measurable clues in samples) to help diagnose and predict outcomes in inflammatory muscle diseases and systemic sclerosis (a skin/organ condition). If you’re being evaluated for myopathy or early scleroderma, it may help doctors sort out the cause and follow your health more closely.
Strasbourg, Bas-RhinAges 18 years+ - NCT05098704RecruitingPhase 2/Phase 3
Clopidogrel to help prevent systemic sclerosis in high-risk people
This study tests whether the medicine clopidogrel can lower the chance of developing systemic sclerosis in adults who have certain blood antibodies and symptoms that suggest higher risk. If you qualify, you would take clopidogrel for the study to see whether it delays or prevents the disease.
BayonneAges 18–85 - NCT06954597RecruitingPhase 2
Testing a new cream for scleroderma finger ulcers
This study tests a new cream (TOP-N53) for digital ulcers caused by scleroderma. The cream is applied directly to the sore, and the goal is to see if it is safe and helps the ulcer heal.
BordeauxAges 18 years+ - NCT07287670RecruitingPhase 2
Testing MTX-474 for diffuse scleroderma
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
Newport Beach, CaliforniaAges 18 years+ - NCT07473154RecruitingPhase 1/Phase 2
Calming an overactive immune system with special cells
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
BirminghamAges 18 years+ - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT07402226Recruiting
Diet study for bloating with scleroderma
This study tests whether a special diet can help reduce bloating and stomach discomfort in people with scleroderma (systemic sclerosis). You'll follow a specific meal plan to see if it improves your digestive symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT05482607Recruiting
CT scan pattern study in lung disease from systemic sclerosis
This study looks at patterns seen on a high-resolution CT (HRCT) scan to better understand lung disease that can occur with systemic sclerosis. It may help doctors recognize which lung changes go with which type of disease.
NancyAges 18 years+
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis?
- Yes. Clin2 currently lists 178 recruiting systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.